| Literature DB >> 30854009 |
Erik W Baars1,2, Eefje Belt-van Zoen2, Thomas Breitkreuz3, David Martin4, Harald Matthes5, Tido von Schoen-Angerer6, Georg Soldner7, Jan Vagedes8, Herman van Wietmarschen1, Olga Patijn1, Merlin Willcox9, Paschen von Flotow10, Michael Teut5, Klaus von Ammon11, Madan Thangavelu12, Ursula Wolf11, Josef Hummelsberger13, Ton Nicolai14, Philippe Hartemann15, Henrik Szőke16, Michael McIntyre17, Esther T van der Werf18,19, Roman Huber20.
Abstract
AIM: The aim of this narrative review was to explore the potential contributions of CAM to reduce antibiotic use.Entities:
Year: 2019 PMID: 30854009 PMCID: PMC6378062 DOI: 10.1155/2019/5365608
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1
Figure 2Worldviews, concepts, and clinical practice.
Studies on prescription and consumption rates of antibiotics in CAM practices and in families with an alternative lifestyle.
| Study type | Results | Study characteristics |
|---|---|---|
| Cross-sectional study comparing children from anthroposophic families and children with a non-anthroposophic lifestyle [ | Past use of antibiotics: | N = 295 anthroposophic children and 380 non-anthroposophic children, age 5-13 years. |
|
| ||
| Cross-sectional study comparing children from anthroposophic families and children with a non-anthroposophic lifestyle [ | Antibiotics use ever, in the first 12 months of life and after 12 months of life: | N = 6.630 children, age 5-13 years (4.606 from Steiner schools and 2.024 from reference schools) in 5 European countries (Austria, 11%; Germany, 39%; The Netherlands, 22%; Sweden, 9%; Switzerland, 20%) |
|
| ||
| KOALA Birth Cohort Study comparing families with an alternative and a non-alternative lifestyle [ | Families with an alternative lifestyle: | N= 2.343 conventional children and 491 alternative lifestyle children. |
|
| ||
| Observational study on prescribing practices of anthroposophic medicine (AM) doctors in the treatment of upper respiratory tract infections [ | Prescription rate for antibiotics (6.3%) was well below the German average | 21.818 prescriptions for 12.081 patients (73.7% children) with 19.050 cases of URTI were analysed. |
|
| ||
| Prospective, non-randomised comparison of outcomes in patients self-selected to anthroposophic or conventional therapy under real-world conditions [ | 5.5% of the patients in the AM group and 33.6% in the conventional group received antibiotics (p < 0.0001) | 29 primary care practices (Austria, Germany, Netherlands, UK and USA). N= 1.016 outpatients, age ≥ 1 month, consulting an anthroposophic (N = 715) or conventional physician (N = 301) with a chief complaint of acute (≤ 7 days) sore throat, ear pain, sinus pain, runny nose or cough |
|
| ||
| Prospective, non-randomised comparison of outcomes in patients self-selected to anthroposophic or conventional therapy under real-world conditions [ | 5.5% of the patients in the AM group and 25.6% in the conventional group received antibiotics (p < 0.001) | N = 529 children <18 years from Europe (Austria, Germany, Netherlands, and UK) or USA with acute respiratory or ear infections |
|
| ||
| Observational study on the treatment of patients with upper respiratory tract infections: homeopathic GPs vs. conventional GPs [ | Significantly lower consumption of antibiotics (OR | N = 518 adults and children with URTI (79.3% rhinopharyngitis). |
|
| ||
| Randomized trial, children 6 months to 11 years old, diagnosed with AOM and managed with a delayed antibiotic approach, randomized to standard therapy alone or standard therapy plus a homeopathic ear drop preparation [ | Significantly less antibiotic use in the homeopathic group (26.9% vs. 41.2%) (p-value not presented) | N = 456 patient visits were compared: 281 received homeopathy, 175 received conventional medicine. |
|
| ||
| Observational study among parents of children [ | Use of homeopathic products not associated with decreased antibiotic consumption (adjusted OR = 1.02, 95% CI: 0.84 - 1.24). | N = 9.723 parents of children, age: 3–4.5 years. |
Cochrane reviews of CAM treatments of infections.
| Treatment and indication | Main conclusions | Study characteristics |
|---|---|---|
|
| ||
|
| ||
| Immunostimulants (IS) (including herbal treatments) for preventing respiratory tract infection in children [ | IS reduce the incidence of acute RTIs by 40% on average in susceptible children | Thirty-five placebo-controlled trials (N = 4.060). |
|
| ||
| Oral | Insufficient evidence of the effectiveness and safety | No studies met the inclusion criteria |
|
| ||
|
| There is insufficient clinical trial evidence | Only one trial met the inclusion criteria. |
|
| ||
|
| There is possibly a weak benefit from some | Twenty-four double-blind trials with 4.631 participants including a total of 33 comparisons of |
|
| ||
|
|
| Of 10 eligible studies, eight were included in the analyses; two were of insufficient quality. Three trials (746 patients, low quality of evidence) of efficacy in acute bronchitis in adults showed effectiveness for most outcomes in the liquid preparation but not for tablets. Three other trials (819 children, low quality of evidence) showed similar results for acute bronchitis in children. |
|
| ||
| Chinese herbals for sore throat [ | Some Chinese herbal medicines appeared efficacious | 12 studies involving 1.954 participants. |
|
| ||
| Chinese medicinal herbs for acute bronchitis [ | There is insufficient quality data | None of 74 studies involving 6.877 participants met the inclusion criteria. |
|
| ||
|
| ||
|
| ||
| Chinese herbal medicine (CHM) for recurrent urinary tract infections [ | CHM as an independent intervention or in conjunction with antibiotics may be beneficial for treating recurrent UTIs during the acute phase of infection and may reduce the recurrent UTI incidence for at least six months post-treatment | Seven RCTs involved a total of 542 women; of these, five recruited post-menopausal women (aged from 56 to 70 years) (422 women). |
|
| ||
| Probiotics for preventing urinary tract infections in adults and children [ | There is insufficient quality data | Nine studies involved 735 people. Four studies compared probiotic with placebo, two compared probiotic with no treatment, two compared probiotics with antibiotics in patients with UTI, and one study compared probiotic with placebo in healthy women. All studies aimed to measure differences in rates of recurrent UTI. |
|
| ||
|
| ||
|
| ||
| Chinese medicinal herbs for preventing infection in nephrotic syndrome [ | A compound of Chinese medicinal herbs— | Twelve studies conducted in China, including 762 children with nephrotic syndrome were identified. No studies were identified in adults. All studies compared one kind of prophylactic pharmacotherapy (intravenous immunoglobulin (IVIG), thymosin, oral transfer factor, mannan peptide tablet, Bacillus Calmette-Guerin (BCG) vaccine injection, polyvalent bacterial vaccine (Lantigen B) and two kinds of Chinese medicinal herbs: a compound of Chinese medicinal herbs ( |
|
| ||
| Honey for infected post-operative wounds [ | Honey appeared to heal infected post-operative wounds more quickly than antiseptics and gauze | One trial (N = 50) on infected post-operative wounds. |
|
| ||
| Chinese herbal medicines for skin and soft-tissue infections [ | No RCTs that met the inclusion criteria > No conclusion | |
Non-Cochrane reviews with some evidence of effectiveness of CAM treatments of infections.
| Treatment and indication | Main conclusions | Study characteristics |
|---|---|---|
|
| ||
|
| ||
|
|
| 33 RCTs with a total of 7.175 patients were included. Most trials evaluating |
|
| ||
|
| Superiority of EPS 7630 to placebo in reducing both symptom severity and time until complete recovery for all indications investigated | 13 trials with a total of 3.392 participants were included, 10 of which could be entered into meta-analyses of efficacy (AB: 6/8 trials; ARS: 2/2 trials; ATP: 2/3 trials). In ARS, all trials included adults only, whereas studies in ATP had been conducted with children only. |
|
| ||
|
| Positive evidence | Seven trials on |
|
| ||
|
| Because of conflicting evidence in the included studies, no concrete conclusion on effects of | Eleven trials with 2.181 participants were included. No clear evidence for |
|
| ||
| Probiotics for prevention of upper respiratory tract infections (URTIs) in children [ | Probiotics decrease the incidence of URTIs | 23 trials with a total of 6.269 children (age: 0 -18). |
|
| ||
| Probiotics for prevention of URTIs in immunocompetent children [ | Modest effect both in diminishing the incidence of URTIs and the severity of the infection symptoms | 14 RCTs applied to a pediatric population with high-quality methodology. |
|
| ||
|
| Higher cure rate and effectiveness rate than control group | Seven studies with 571 URTI patients. |
|
| ||
|
| Better effect than common antibiotics on helping relieve some symptoms and decrease the course of acute upper respiratory tract infections | Eight trials with 857 participants. |
|
| ||
| Homeopathy for URTIs [ | Positive results | 29 studies of different designs (17 RCTs) with 5.062 patients on the domain ‘Upper Respiratory Tract Infection/Allergy' (URTI/A) showed an overall positive result in favour of homeopathy. 6 out of 7 of the controlled studies demonstrated at least equivalence with conventional medical interventions and 8 out of 16 placebo controlled studies significance in favour of homeopathy. This positive trend was maintained in the evaluation of subgroups. |
|
| ||
| Individualized homeopathy for children with URTI, tonsillitis and acute sinusitis [ | Homeopathy is a more or at least not inferior cost-effective method than placebo or conventional and antibiotic treatments | Six clinical trials (N= not presented). |
|
| ||
| Herbal medicine for cough [ | Strong evidence for | 34 RCTs (N = 7.083) on |
|
| ||
| Chinese herbal medicine for postinfectious cough [ | Improvement of core symptoms of postinfectious cough | 12 RCTs with moderate-to-high levels of evidence. Methodological quality was considered high in three trials, while in the other nine studies the unclear risk of bias was in the majority. Findings suggested that, compared with western conventional medicine or placebo, Chinese herbal medicine could effectively improve core symptoms of postinfectious cough, act better and have earlier antitussive effect, and enhance patients' quality of life. No serious adverse event was reported. |
|
| ||
| Chinese medicine for respiratory diseases [ | Chinese medicine was more effective than anti-viral medicine | Six economic evaluations and cost studies were included, of which 4 studies' quality was low, 1 was high and 1 was medium. All studies adequately documented effectiveness of interventions. However, the costs of interventions were not well reported in 2 studies. 2 studies inadequately conducted sensitivity analysis and discounting. The diseases of 6 studies included bronchitis (2 studies), upper respiratory tract infection, herpangina, hand-foot-and-mouth disease and viral pneumonia. The studies results showed that cost-effectiveness of |
|
| ||
|
| ||
|
| ||
| Cranberry for UTIs [ | Evidence supporting clinical efficacy of cranberry product UTI prophylaxis exists in the following populations: women with rUTI, women with rUTI over 49 years old, children, rUTI, post-gynecological surgery patients, patients carrying a double-J ureteral stent, high-UTI-risk long-term care facility (LTCF) patients, prostatic adenocarcinoma patients treated with radiotherapy, and renal transplant patients with rUTI. | 22 relevant articles: three SRs, two SRs with MAs, eight RCTs, five NRSs, and four guidelines with relevant recommendations. |
|
| ||
|
| ||
|
| ||
| Probiotics for antibiotic-associated diarrhoea (AAD) [ | Reduction of AAD | A total of 82 RCTs met inclusion criteria. The majority used Lactobacillus-based interventions alone or in combination with other genera; strains were poorly documented. The pooled relative risk in a DerSimonian-Laird random-effects meta-analysis of 63 RCTs, which included 11.811 participants, indicated a statistically significant association of probiotic administration with reduction in AAD (relative risk: 0.58; 95% CI: 0.50-0.68; p < .001; I(2), 54%; [risk difference: -0.07; 95% CI, -0.10 to -0.05], [number needed to treat: 13; 95% CI: 10.3-19.1]) in trials reporting on the number of patients with AAD. This result was relatively insensitive to numerous subgroup analyses. However, there exists significant heterogeneity in pooled results and the evidence is insufficient to determine whether this association varies systematically by population, antibiotic characteristic, or probiotic preparation. |
|
| ||
| Probiotics for prevention of AAD [ | Preventive effects on AAD in adults (18–64 years) but not the elderly (> 65 years) | 30 RCTs met the predefined inclusion criteria and were included in the meta-analysis. |